Dystrophic Epidermolysis Bullosa Pipeline Drugs Report 2025: Comprehensive Insights into Emerging Therapies, Clinical Trials, and Market Opportunities Shaping SMA Treatment Landscape

DelveInsight's, "Dystrophic Epidermolysis Bullosa Pipeline Insight, 2025," report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Dystrophic Epidermolysis Bullosa pipeline landscape. It covers the Dystrophic Epidermolysis Bullosa pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Dystrophic Epidermolysis Bullosa pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight's comprehensive Dystrophic Epidermolysis Bullosa Pipeline Report to explore emerging therapies, key companies, and future treatment landscapes @ Dystrophic Epidermolysis Bullosa Pipeline Outlook Report- https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Dystrophic Epidermolysis Bullosa Pipeline Report
• In August 2025, Krystal Biotech Inc. announced a Phase 3 study, to evaluate the safety and efficacy of KB803 versus matched placebo in pediatric and adult subjects with recurrent corneal abrasions due to dystrophic epidermolysis bullosa (DEB).
• In August 2025, Castle Creek Biosciences LLC conducted a study is to determine whether administration of D-Fi in addition to standard of care improves wound healing as compared to standard of care alone (control) in children, adolescents, and adults with Dystrophic Epidermolysis Bullosa.
• DelveInsight's Dystrophic Epidermolysis Bullosa pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Dystrophic Epidermolysis Bullosa treatment.
• The leading Dystrophic Epidermolysis Bullosa Companies such as Phoenix Tissue Repair, Castle Creek Biosciences, Phoenicis Therapeutics, Aegle Therapeutics, RHEACELL GmbH & Co. KG, Anterogen Co., Ltd., Abeona Therapeutics, Inc, InMed Pharmaceuticals, BridgeBio Inc., Eloxx Pharmaceuticals, Relief Therapeutics, Quoin Pharmaceuticals and others.
• Promising Dystrophic Epidermolysis Bullosa Pipeline Therapies such as KB803, AGLE-102, EB-101, PTR-01, Oleogel-S10, INM-755 (cannabinol) cream, and others.

Discover how the Dystrophic Epidermolysis Bullosa treatment paradigm is evolving. Access DelveInsight's in-depth pipeline analysis for a closer look at promising breakthroughs @ Dystrophic Epidermolysis Bullosa Clinical Trials and Studies- https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Dystrophic Epidermolysis Bullosa Emerging Drugs Profile
• PTR-01: Phoenix Tissue Repair
Phoenix Tissue Repair is advancing an investigational therapy known as PTR-01, a systemic recombinant collagen type VII (rC7) for the treatment of Recessive Dystrophic Epidermolysis Bullosa. rC7 is a potentially disease-modifying drug that is delivered intravenously to patients, replacing defective collagen type VII with healthy collagen at the sites where it is needed both internally and externally. Phoenix Tissue Repair acquired worldwide rights to PTR-01 from Shire Plc in 2017 and has initiated its first clinical trial. Preclinical studies of PTR-01 have shown that it selectively anchors in the skin and other tissues affected by an absence of collagen type VII. In four animal models of the disease, intravenous injections of PTR-01 promoted healing of DEB wounds. These experiments have shown improvements in tissue structure, disease presentation and survival, indicating a restoration of natural skin architecture.

• FCX-007: Castle Creek Biosciences
D-Fi, also known as FCX-007, (dabocemagene autoficel), is being developed as an ex vivo, autologous cell-based gene therapy to address the deficiency of functional COL7 in patients with dystrophic epidermolysis bullosa (DEB). D-Fi has been clinically studied in a Phase 1/2 clinical study (NCT02810951), which assessed 6 patients with RDEB. In this study, 80% (8/10) of treated chronic wounds demonstrated complete wound healing 12 weeks after the first injection of D-Fi, while none of the untreated wounds were healed. D-Fi was well tolerated post-administration with few reports of temporary redness or discoloration at the injection site. D-Fi is currently in Phase 3 clinical development for the localized treatment of chronic wounds in individuals with RDEB.

The Dystrophic Epidermolysis Bullosa Pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Dystrophic Epidermolysis Bullosa with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dystrophic Epidermolysis Bullosa Treatment.
• Dystrophic Epidermolysis Bullosa Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Dystrophic Epidermolysis Bullosa Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dystrophic Epidermolysis Bullosa market.

Get a detailed analysis of the latest innovations in the Dystrophic Epidermolysis Bullosa pipeline. Explore DelveInsight's expert-driven report today! @ Dystrophic Epidermolysis Bullosa Unmet Needs- https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Dystrophic Epidermolysis Bullosa Companies
Phoenix Tissue Repair, Castle Creek Biosciences, Phoenicis Therapeutics, Aegle Therapeutics, RHEACELL GmbH & Co. KG, Anterogen Co., Ltd., Abeona Therapeutics, Inc, InMed Pharmaceuticals, BridgeBio Inc., Eloxx Pharmaceuticals, Relief Therapeutics, Quoin Pharmaceuticals and others.

Dystrophic Epidermolysis Bullosa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Dystrophic Epidermolysis Bullosa Products have been categorized under various Molecule types such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Download DelveInsight's latest report to gain strategic insights into upcoming Dystrophic Epidermolysis Bullosa Therapies and key Developments @ Dystrophic Epidermolysis Bullosa Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Dystrophic Epidermolysis Bullosa Pipeline Report
• Coverage- Global
• Dystrophic Epidermolysis Bullosa Companies- Phoenix Tissue Repair, Castle Creek Biosciences, Phoenicis Therapeutics, Aegle Therapeutics, RHEACELL GmbH & Co. KG, Anterogen Co., Ltd., Abeona Therapeutics, Inc, InMed Pharmaceuticals, BridgeBio Inc., Eloxx Pharmaceuticals, Relief Therapeutics, Quoin Pharmaceuticals and others.
• Dystrophic Epidermolysis Bullosa Pipeline Therapies- KB803, AGLE-102, EB-101, PTR-01, Oleogel-S10, INM-755 (cannabinol) cream, and others.
• Dystrophic Epidermolysis Bullosa Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Dystrophic Epidermolysis Bullosa Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Dystrophic Epidermolysis Bullosa drug development? Find out in DelveInsight's exclusive pipeline report-access it now! @ Dystrophic Epidermolysis Bullosa Emerging Drugs and Major Companies- https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Introduction
2. Executive Summary
3. Dystrophic Epidermolysis Bullosa: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Dystrophic Epidermolysis Bullosa - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. FCX-007: Castle Creek Biosciences
9. Mid Stage Products (Phase II)
10. PTR-01: Phoenix Tissue Repair
11. Early Stage Products (Phase I/II)
12. PTW-002: Phoenicis Therapeutics
13. Preclinical and Discovery Stage Products
14. Drug name: Company name
15. Inactive Products
16. Dystrophic Epidermolysis Bullosa Key Companies
17. Dystrophic Epidermolysis Bullosa Key Products
18. Dystrophic Epidermolysis Bullosa- Unmet Needs
19. Dystrophic Epidermolysis Bullosa- Market Drivers and Barriers
20. Dystrophic Epidermolysis Bullosa- Future Perspectives and Conclusion
21. Dystrophic Epidermolysis Bullosa Analyst Views
22. Dystrophic Epidermolysis Bullosa Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.